BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5-11 Years of Age: A Test Negative Design.

BNT162b2 COVID-19 Kaiser Permanente SARS-CoV-2 United States booster delta effectiveness omicron pediatric real-world test-negative

Journal

Journal of the Pediatric Infectious Diseases Society
ISSN: 2048-7207
Titre abrégé: J Pediatric Infect Dis Soc
Pays: England
ID NLM: 101586049

Informations de publication

Date de publication:
18 Apr 2023
Historique:
received: 27 10 2022
accepted: 26 01 2023
medline: 20 4 2023
pubmed: 31 1 2023
entrez: 30 1 2023
Statut: ppublish

Résumé

In a 1:1 matched test-negative design among 5- to 11-year-olds in the Kaiser Permanente Southern California health system (n = 3984), BNT162b2 effectiveness against the omicron-related emergency department or urgent care encounters was 60% [95%CI: 47-69] <3 months post-dose-two and 28% [8-43] after ≥3 months. A booster improved protection to 77% [53-88].

Identifiants

pubmed: 36715070
pii: 7008779
doi: 10.1093/jpids/piad005
pmc: PMC10112675
doi:

Substances chimiques

BNT162 Vaccine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

177-179

Subventions

Organisme : Pfizer

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society.

Références

MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):422-428
pubmed: 35298453
Perm J. 2012 Summer;16(3):37-41
pubmed: 23012597
N Engl J Med. 2022 Aug 11;387(6):525-532
pubmed: 35857701
JAMA Netw Open. 2022 Dec 1;5(12):e2246915
pubmed: 36515946
Lancet Respir Med. 2022 Jul;10(7):689-699
pubmed: 35468336
Lancet Infect Dis. 2022 May;22(5):581-583
pubmed: 35325619
N Engl J Med. 2022 Oct 6;387(14):1332-1333
pubmed: 36103455
MMWR Morb Mortal Wkly Rep. 2022 Mar 04;71(9):352-358
pubmed: 35239634
Lancet. 2022 Jul 9;400(10346):97-103
pubmed: 35780801
N Engl J Med. 2022 Jul 21;387(3):227-236
pubmed: 35767475
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
N Engl J Med. 2022 May 19;386(20):1899-1909
pubmed: 35353976
Lancet Reg Health Am. 2022 Apr;8:100246
pubmed: 35399648
JAMA. 2022 Jan 4;327(1):23-25
pubmed: 34910088
MMWR Morb Mortal Wkly Rep. 2021 Nov 12;70(45):1579-1583
pubmed: 34758012
Am J Epidemiol. 2021 May 4;190(5):918-927
pubmed: 33124649
Lancet Reg Health Am. 2022 May;9:100198
pubmed: 35187521

Auteurs

Sara Y Tartof (SY)

Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.
Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.

Timothy B Frankland (TB)

Kaiser Permanente Hawaii Center for Integrated Health Care Research, Honolulu, Hawaii, USA.

Laura Puzniak (L)

Pfizer Inc., Collegeville, Pennsylvania, USA.

Jeff M Slezak (JM)

Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.

Vennis Hong (V)

Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.

Harpreet Takhar (H)

Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.

Oluwaseye A Ogun (OA)

Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.

Sarah Simmons (S)

Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.

Fagen Xie (F)

Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.

Joann Zamparo (J)

Pfizer Inc., Collegeville, Pennsylvania, USA.

Bradley K Ackerson (BK)

Southern California Permanente Medical Group, Harbor City, California, USA.

Luis Jodar (L)

Pfizer Inc., Collegeville, Pennsylvania, USA.

John M McLaughlin (JM)

Pfizer Inc., Collegeville, Pennsylvania, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH